Antifibrinolytic therapy in the management of the kasabach merritt syndrome

✍ Scribed by Dr. Thomas L. Ortel; James J. Onorato; Camille L. Bedrosian; Russel E. Kaufman

• Publisher: John Wiley and Sons
• Year: 1988
• Tongue: English
• Weight: 488 KB
• Volume: 29
• Category: Article
• ISSN: 0361-8609
• DOI: 10.1002/ajh.2830290111

✦ Synopsis

The Kasabach Merritt syndrome consists of thrombocytopenla, mlcroangiopathic hemolytic anemia, and a localized consumption coagulopathy that develops within the abnormal vascular channels of a hemangloma. In general, these patients demonstrate only mild ebnormalltles of screening clotting tests, but they can potentially develop lifethreatening complications. We present a patient who developed a severe anemia that was refractory to erythrocyte transfusions. Treatment with epsllon-aminocaproic acid to inhibit fibrinolysis and cryoprecipitate to replenish hls deficient circulating flbrlnogen interrupted the cycle of his systemic coagulopathy and enabled us to transfuse him to a normal hematocrit.